• 12 hours Gold Miners Brace For Seasonal Downturn
  • 19 hours The Silver Plunge Continues
  • 1 day 7 COVID Vaccine Stocks To Plan Upside Moves
  • 2 days Rhodium Climbs Reaches Record Highs
  • 2 days Tesla Tumbles After Battery Day Fails To Impress
  • 3 days Three Energy ETFs To Watch This Decade
  • 3 days What To Do With $2 Trillion In Suspicious Bank Transactions?
  • 4 days How The Stock Market Predicts Electoral Victory
  • 5 days Tesla's "Battery Day" Could Deal A Blow To Cobalt Miners
  • 5 days New TikTok Deal Hopes To Bypass National Security Concerns
  • 6 days Where Will Gold Go From Here?
  • 6 days COVID-19 Is Fueling A Pastic Waste Crisis
  • 7 days Gold Output Set To Decline
  • 8 days Uber And Lyft Look To Go Electric
  • 9 days COVID-19 Is Crushing Palladium Demand
  • 9 days This ‘Once-Boring’ Tech Company Is Now Super Hot
  • 10 days Will Air-Based Protein Be Our Future Food?
  • 11 days Google Pledges To Go Carbon-Free By 2030
  • 11 days A New Twist In The TikTok Saga
  • 12 days Gold Inches Closer To $2,000
Chinese E-Commerce Giant Eyes Aggressive Expansion

Chinese E-Commerce Giant Eyes Aggressive Expansion

China’s second largest e-commerce site…

Oxford Business Group

Oxford Business Group

Oxford Business Group

The global economic landscape is changing, and since 1994 OBG has been at the frontier of mapping new waves of emerging economies. OBG now operates in…

Contact Author

  1. Home
  2. Markets
  3. Emerging Markets

Emerging Economies Could Get Left Behind In Race For COVID Vaccine

COVID Vaccine

With 20m people infected globally and 735,000 virus-related deaths as of August 10, it is becoming increasingly clear that a vaccine is required for societies and economies to return to a sense of normality.

At present, researchers around the world are working on more than 150 different vaccines, with 26 already reaching the human trial stage.

The issue presents an interesting conundrum for emerging markets, amid concerns that many may miss out on early access to vaccines in favour of wealthier countries.

In late July the US government announced that it had signed a $2bn contract with US multinational Pfizer and German company BioNTech to develop 100m coronavirus vaccines by the end of the year, while in June Germany invested €300m – a 23% stake – in local biopharmaceutical company CureVac, which is working on a Covid-19 vaccine.

China, meanwhile, has also invested heavily in a number of domestic companies, with international media reporting that it had spent around $140bn on measures to fight the virus, including the development of treatments and vaccines.

Testing moves forward

Some emerging markets have sought to position themselves favourably for vaccine access by collaborating with international pharmaceutical companies on testing.

In the Middle East, Saudi Arabia, the UAE and Bahrain have begun clinical testing for a virus vaccine in cooperation with Chinese companies.

The third-phase testing for the potential vaccine will see around 5000 adults in each country take part in the trial.

Meanwhile in Asia, Indonesian state-owned company Bio Farma has partnered with China’s Sinovac to conduct phase-three vaccine trials in West Java, while local health giant Kalbe Farma is also teaming up with South Korea’s Genexine for phase-two testing of the company’s vaccine.

In addition, a national consortium under the Ministry of Research and Technology has begun working on a longer-term, self-sufficient strategy to develop its own vaccine.

Meanwhile, similar efforts towards vaccine self-sufficiency are under way in Peru and Mexico.

Beyond vaccine diplomacy

The ability of emerging markets to develop working relationships with leading medical research nations is seen as key to gaining access to future vaccines.

For instance, China has indicated that it would give the Philippines priority access to any vaccine that it develops.

The importance of strong ties with wealthier countries comes amid concerns that they may outbid emerging markets once approved solutions enter the market, subsequently leaving lower-income nations at the back of the queue. Related: Crypto FOMO Heats Up As Bitcoin Climbs Above $11,000

In fact, the World Health Organisation has warned against so-called “vaccine nationalism”, noting that – given the interconnected nature of the world economy – it would be in the general interest to share the benefits of any potential vaccine.

To avoid such a situation, an international coalition of organisations has developed the COVAX Facility, a mechanism designed to provide rapid, fair and equitable access to Covid-19 vaccines globally.

The initiative involves high- and middle-income countries financing vaccines through their own public budgets, then teaming up with lower-income nations to provide support in the form of voluntary donations to the COVAX Advance Market Commitment, run by Gavi, the Vaccine Alliance.

So far 75 countries have expressed interest in funding the initiative, which would benefit 90 lower-income nations.

The goal is to deliver 2bn doses of approved vaccines by the end of next year. Under the plans, they would be delivered equally to all participating nations, proportional to their populations, and would initially prioritise health care workers.

By Oxford Business Group 

More Top Reads From Safehaven.com:

Back to homepage

Leave a comment

Leave a comment